贝伐珠单抗联合GC化疗方案治疗晚期非小细胞肺癌患者的效果

Efficacy of Bevacizumab Combined with GC Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

目的:分析贝伐珠单抗联合吉西他滨+顺铂(GC)化疗方案治疗晚期非小细胞肺癌(NSCLC)患者的效果。方法:回顾性分析2020年8月—2023年8月平邑县人民医院收治的82例晚期NSCLC患者资料,根据治疗方式的不同将其分为对照组和研究组,各41例。对照组采用GC化疗方案治疗,研究组在对照组基础上采用贝伐珠单抗治疗。比较两组临床疗效、肿瘤标志物、免疫功能、不良反应发生情况。结果:研究组治疗总有效率为90.24%,高于对照组的70.73%,+差异有统计学意义(P<0.05)。治疗后,研究组癌胚抗原、糖类抗原125、糖类抗原199、CD8分别为(5.05±0.89)ng/mL、(35.41±2.96)U/mL、(36.25±3.84)U/mL、(25.29±1.72)%,均低于对照组的(8.21±1.57)ng/mL、(42.33±4.29)U/mL、(42.53±4.23)U/mL、(34.35±3.79)%,CD3^(+)、CD4^(+)分别为(67.95±6.26)%、(39.24±2.86)%,均高于对照组的(53.50±4.75)%、(30.18±1.96)%,差异均有统计学意义(P<0.05)。研究组不良反应发生率为12.20%,低于对照组的19.51%,但两组比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗联合GC化疗方案应用于晚期NSCLC患者中效果良好,能够改善患者免疫功能,降低肿瘤标志物水平,且具有一定安全性。

Objective:To analyze the efficacy of Bevacizumab combined with Gemcitabine+Cisplatin(GC)in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods:The data of 82 patients with advanced NSCLC treated in Pingyi County People’s Hospital from August 2020 to August 2023 were retrospectively analyzed,and they were divided into a control group and a study group according to different treatment methods,with 41 cases in each group.The control group was treated with GC chemotherapy regimen,and the study group was treated with Bevacizumab based on the control group.The clinical efficacy,tumor markers,immune function and occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 90.24%,which was higher than 70.73%of the control group,the difference was statistically significant(P<0.05).After treatment,carcino-embryonic antigen,carbohydrate antigen 125,carbohydrate antigen 199,CD8^(+)of the study group were(5.05±0.89)ng/mL,(35.41±2.96)U/mL,(36.25±3.84)U/mL,(25.29±1.72)%,respectively,which were lower than(8.21±1.57)ng/mL,(42.33±4.29)U/mL,(42.53±4.23)U/mL,(34.35±3.79)%of the control group,the CD3^(+)and CD4^(+)were(67.95±6.26)%and(39.24±2.86)%,respectively,which were higher than(53.50±4.75)%and(30.18±1.96)%in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 12.20%,which was lower than 19.51%in the control group,but there was no statistical significance between the two groups(P>0.05).Conclusion:Bevacizumab combined with GC chemotherapy is effective in patients with advanced NSCLC,can improve the immune function of patients,reduce the level of tumor markers,and has a certain safety.